Inclusion Criteria

Inclusion criteria:

1. Male or female patients ≥ 18 years of age.

2. ECOG 0, 1, or 2.

3. Patients with Ph+ CML who have failed treatment in the core protocol.

4. Diagnosis of chronic myelogenous leukemia with cytogenetic confirmation of
Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL a review of a
minimum 20 metaphases is required).

5. Adequate end organ function as defined by:

- Total bilirubin < 1.5 x ULN,

- SGOT and SGPT < 2.5 x ULN,

- Creatinine < 1.5 x ULN,

- Serum amylase and lipase ≤ 1.5 x ULN,

- Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.

6. Patients must have the following laboratory values (≥ LLN (lower limit of normal) or
corrected to within normal limits with supplements prior to the first dose of study
medication.):

- Potassium ≥ LLN,

- Magnesium ≥ LLN,

- Phosphorus ≥ LLN,

- Total calcium (corrected for serum albumin) ≥ LLN.

Exclusion criteria:

1. Previously documented T315I mutations.

2. Impaired cardiac function including any one of the following:

- LVEF < 45% or below the institutional lower limit of the normal range (whichever
is higher) as determined by locally read echocardiogram.

- Inability to determine the QT interval on ECG.

- Complete left bundle branch block.

- Use of a ventricular-paced pacemaker.

- Congenital long QT syndrome or a known family history of long QT syndrome.

- History of or presence of clinically significant ventricular or atrial
tachyarrhythmias.